The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study

Authors

  • G. Cohen,

    1. Hospital Oral Medicine Department, Hadassah, Hebrew University, School of Dental Medicine, Founded by the Alpha Omega Fraternity, Jerusalem 91120
    Search for more papers by this author
  • S. Elad,

    Corresponding author
    1. Hospital Oral Medicine Department, Hadassah, Hebrew University, School of Dental Medicine, Founded by the Alpha Omega Fraternity, Jerusalem 91120
    Search for more papers by this author
  • R. Or,

    1. Hebrew University Medical School, Department of Hone Marrow Transplantation and Cancer lmmunobiology Research Laboratory, Hadassah University Hospital, 91120 Jerusalem, Israel
    Search for more papers by this author
  • D. Galili,

    1. Hospital Oral Medicine Department, Hadassah, Hebrew University, School of Dental Medicine, Founded by the Alpha Omega Fraternity, Jerusalem 91120
    Search for more papers by this author
  • A.A. Garfunkel

    1. Hospital Oral Medicine Department, Hadassah, Hebrew University, School of Dental Medicine, Founded by the Alpha Omega Fraternity, Jerusalem 91120
    Search for more papers by this author

Hospital Oral Medicine Department, Hadassah Hebrew University, School of Dental Medicine, POB 12000, 91120 Jerusalem, Israel

Abstract

OBJECTIVE: The examination of prophylactic efficacy of tretinoin on oral mucositis, post bone marrow transplantation (BMT).

PATIENTS AND METHODS: The study population consisted of 11 patients undergoing BMT.Six tretinoin topically-treated patients (0.25 mg daily of 0.1 % tretinoin cream) were matched with five non-treated control patients comparing mucositis severity, duration and analgetic (morphine) requirementS. Concomitant follow-up included conditioning parameters associated with mucositis and engraftment.

RESULTS: The mean of oral mucositis peak scores was significantly lower in the tretinoin-treated patients vs the non-treated patients (score 1.5 vs 3.6; P < 0.02). In the majority of cases the duration of the most severe phase of oral mucositis was shorter in the tretinoin-treated group as compared with the control. Only one patient in the experimental group required morphine analgesics compared with four patients in the control group.

CONCLUSIONS: This preliminary study indicates that the severity of oral mucositis, both objective and subjective, in BMT patients may be reduced by 0.1% topical tretinoin cream, 0.25 mg, administered daily from the beginning of the BMT conditioning regimen until marrow engraftment.

Ancillary